Study of immune proteins in blood vessel damage after transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at how two immune system proteins, interferon and complement, are involved in a rare condition called thrombotic microangiopathy (TMA) that can damage small blood vessels after a stem cell or organ transplant. Understanding these proteins may help doctors find better treatments for TMA and related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant (from yourself or a donor) or an organ transplant.
- You have a diagnosis of TMA (based on symptoms or a biopsy) OR you have a viral infection after transplant OR you have no infection and no TMA after transplant.
- You do not have a history of aHUS (a related kidney condition) or malignant hypertension.
- You have not been treated with complement inhibitors or anti-interferon drugs before.
- You are not pregnant, breastfeeding, or planning to become pregnant within the next year (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This study tracks patients who receive a stem cell transplant from a donor to see how often they develop a blood condition called transplant-associated thrombotic microangiopathy (TA-TMA). The goal is to identify patients at higher risk and monitor them closely for this condition.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.